Plus Therapeutics, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, specializing in the development of targeted radiotherapeutics and diagnostic services for central nervous system (CNS) cancers. The company’s primary products include REYOBIQ™ (rhenium Re-186 obisbemeda), an investigational liposomal radiopharmaceutical aimed at treating recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. It also offers CNSide®, a molecular diagnostic cerebrospinal fluid (CSF) assay platform designed to support rapid diagnosis and treatment monitoring of CNS cancers. Additionally, Plus Therapeutics is developing Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere (188NL-BAM) for treating solid organ cancers including primary and secondary liver cancers. Recent major developments include the commercial launch of the CNSide CSF diagnostics platform, receiving the first national coverage agreement with UnitedHealthcare effective September 2025, covering over 51 million people in the U.S., and achieving CLIA accreditation for its Houston laboratory. The company demonstrated positive interim Phase 1 clinical trial results for REYOBIQ™ in leptomeningeal metastases, showing favorable safety and efficacy signals. Plus Therapeutics has strengthened its financial position with a $17.6 million Cancer Prevention and Research Institute of Texas (CPRIT) grant, advanced private placements, and regained Nasdaq listing compliance. In 2025, it also appointed Kyle Guse to its Board of Directors, enhancing its governance with his financial and legal expertise. Founded in 2014, Plus Therapeutics operates primarily in the biotechnology and pharmaceutical sectors, focusing on difficult-to-treat cancers of the CNS and solid organs. It leverages proprietary nanoliposome technology to deliver targeted radioisotope therapies directly to tumors using convection-enhanced delivery (CED) and standard medical access techniques such as Ommaya reservoirs. The company’s products and clinical programs target adult and pediatric patients with rare and challenging cancers, conducting clinical trials across the U.S. and collaborating with leading cancer centers. Plus Therapeutics combines innovation in radiopharmaceutical drug delivery with advanced diagnostic platforms to improve patient outcomes in oncology.
Company News
Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines
Cerenome Reports Second Quarter 2026 Financial Results and Business Update
Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives
Plus Therapeutics, Inc. (NASDAQ:PSTV) Receives Consensus Recommendation of “Hold” from Brokerages
Cerenome Launches as an Integrated CNS Oncology Company
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference
Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform
Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring
Plus Therapeutics, Inc. (PSTV) Discusses Rebranding and Integrated CNS Oncology Platform Strategy Transcript
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding
Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
Plus Therapeutics to Provide Business Update Call on June 30, 2026
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics gains CAP accreditation for CNSide CSF assay platform
Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory
Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases
Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology